newsfilter
← Latest News
Business Wire·

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond